Skip to main content
Frontier Biotechnologies Inc. logo

Frontier Biotechnologies Inc. — Investor Relations & Filings

Ticker · 688221 ISIN · CNE100005XF5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2021-04-23 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 688221

About Frontier Biotechnologies Inc.

https://www.frontierbiotech.com/

Frontier Biotechnologies Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines, particularly in the field of anti-infectives. The company's flagship product is albuvirtide, a long-acting HIV fusion inhibitor administered via injection. This therapeutic represents a significant advancement in HIV management by providing a long-acting alternative to daily oral regimens. Frontier Biotechnologies maintains a diverse pipeline of clinical-stage candidates, including protease inhibitors developed for the treatment of COVID-19. The company leverages its proprietary technology platforms to develop long-acting peptide drugs and small molecule therapeutics targeting unmet medical needs in infectious diseases and chronic conditions. Its core operations encompass the full drug development lifecycle, from discovery and clinical trials to manufacturing and commercial distribution.

Recent filings

Filing Released Lang Actions
前沿生物2020年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the resolutions passed at the 2020 Annual General Meeting (AGM) of the company, including voting results on various proposals such as the 2020 annual report, financial reports, profit distribution plan, and appointment of auditors. It details the meeting date, attendance, voting procedures, and vote counts. The document does not contain the full annual report or financial statements but rather the official voting results and decisions made at the AGM. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 3359 characters, which is consistent with an announcement rather than a full report.
2021-04-23 Chinese
前沿生物首次公开发行网下配售限售股上市流通公告
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement regarding the listing and circulation of restricted shares from a company's initial public offering (IPO) on the Shanghai Stock Exchange. It includes specifics about the number of shares, lock-up periods, shareholder commitments, regulatory approvals, and a detailed list of shareholders and their holdings. The content focuses on the release of restricted shares for trading after the lock-up period, which is a capital market event related to share circulation and capital structure changes. It is not a financial report, earnings release, or management discussion. It is also not a proxy, AGM material, or legal proceeding. The document is an official announcement about the capital change event of restricted shares becoming tradable. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length and detail confirm it is not a mere announcement of a report but a substantive disclosure about capital changes.
2021-04-19 Chinese
瑞银证券有限责任公司关于前沿生物药业（南京）股份有限公司首次公开发行网下配售限售股上市流通之核查意见
Regulatory Filings
2021-04-19 Chinese
前沿生物2020年年度股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as the 2020 Annual General Meeting (AGM) materials for the company 前沿生物药业（南京）股份有限公司. It contains detailed meeting notices, agenda, and multiple proposals to be discussed and voted on during the AGM, including reports such as the 2020 Board of Directors Work Report, Independent Directors' Report, Supervisory Board Report, Financial Final Accounts Report, 2020 Annual Report and its summary, profit distribution plan, and appointment of auditing institutions. The document also includes detailed instructions for shareholders on meeting procedures, voting methods, and other AGM-related information. The content is clearly the presentation and materials shared during the Annual General Meeting, not the annual report itself or an announcement of the report. The document length is substantial (15,000 characters), and it contains substantive meeting materials and agenda items. Therefore, the document fits the category of AGM Information (AGM-R).
2021-04-15 Chinese
上海信公轶禾企业管理咨询有限公司关于前沿生物药业（南京）股份有限公司2021年限制性股票激励计划限制性股票首次授予相关事项之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" regarding a 2021 restricted stock incentive plan for a company. It contains detailed information about the stock incentive plan, including the number of shares, grant dates, pricing, vesting conditions, approval procedures, and lists of recipients. The document is comprehensive and lengthy (15,000 characters), indicating it is the full report rather than a brief announcement. The content focuses on stock incentive plans and related financial advisory opinions, which aligns with a Capital/Financing Update category rather than an annual report or earnings release. It is not a regulatory filing or announcement of a report, but a detailed advisory report on a financing-related equity incentive plan. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-03-30 Chinese
前沿生物2021年限制性股票激励计划首次授予激励对象名单（截止授予日）
Director's Dealing Classification · 95% confidence The document is a list of recipients for a 2021 restricted stock incentive plan, detailing allocations of restricted stock to directors, senior management, and other employees. It includes specific names, positions, and stock quantities granted. This type of document is related to share-based compensation and insider share transactions rather than a financial report or announcement of voting results. It is not an annual report, earnings release, or management discussion. It is also not a regulatory filing or announcement of a report publication. The document fits best under 'Director's Dealing' (DIRS) because it reports personal share transactions or grants to company directors and executives as part of an equity incentive plan.
2021-03-30 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.